Skip Navigation


Carcinogenesis Advance Access originally published online on May 22, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/8/1337    most recent
bgg086v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bhakat, K. K.
Right arrow Articles by Mitra, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhakat, K. K.
Right arrow Articles by Mitra, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 24, No. 8, 1337-1345, August 2003
© 2003 Oxford University Press

CANCER BIOLOGY

CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration

Kishor K. Bhakat and Sankar Mitra1

Sealy Center for Molecular Science and Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, 6.136 Medical Research Building, Route 1079, Galveston, TX 77555, USA

1 To whom correspondence should be addressed Email: samitra{at}utmb.edu

The mechanism of inactivation of the O6-methylguanine-DNA methyltransferase (MGMT), responsible for repair of mutagenic and cytotoxic O6-alkylguanine, in Mex- tumor cells, is not completely understood. We have examined the role of CpG methylation in the human MGMT promoter in a luciferase (luc) reporter plasmid and associated alteration in chromatin structure. Methylation of 16% CpG sequences in promoter and flanking sequences in the plasmid with HpaII methylase reduced luciferase activity by 10–12-fold, while methylation of all CpG sites, including those in the luc coding sequence, as well as the promoter sequence blocked expression completely. Repression of luc expression due to partial but not complete CpG methylation could be reversed by histone deacetylase inhibitor trichostatin A (TSA). However, 5-azacytidine, which reverses CpG methylation, but not TSA, could reactivate silent MGMT gene in Mex- HeLa MR cells. Furthermore, chromatin immunoprecipitation (ChIP) assay showed reduced level of acetylation of H4 histone bound to the methylated promoter compared with the non-methylated promoter. These results suggest that complete repression of the MGMT gene in Mex- cells requires methylation of CpG sequences in both promoter and neighboring regions of the gene, resulting in inactive, condensed chromatin state of the gene.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
D. BOCANGEL, S. SENGUPTA, S. MITRA, and K. K. BHAKAT
p53-Mediated Down-regulation of the Human DNA Repair Gene O6-Methylguanine-DNA Methyltransferase (MGMT) via Interaction with Sp1 Transcription Factor
Anticancer Res, October 1, 2009; 29(10): 3741 - 3750.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncologyHome page
G. J. Kitange, B. L. Carlson, M. A. Schroeder, P. T. Grogan, J. D. Lamont, P. A. Decker, W. Wu, C. D. James, and J. N. Sarkaria
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Neuro Oncology, June 1, 2009; 11(3): 281 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Fontijn, A. D. Adema, K. K. Bhakat, H. M. Pinedo, G. J. Peters, and E. Boven
O6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells
Mol. Cancer Ther., October 1, 2007; 6(10): 2807 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Lavon, D. Zrihan, B. Zelikovitch, Y. Fellig, D. Fuchs, D. Soffer, and T. Siegal
Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas
Clin. Cancer Res., March 1, 2007; 13(5): 1429 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Brell, A. Tortosa, E. Verger, J. M. Gil, N. Vinolas, S. Villa, J. J. Acebes, L. Caral, T. Pujol, I. Ferrer, et al.
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas
Clin. Cancer Res., July 15, 2005; 11(14): 5167 - 5174.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. P. Danam, S. R. Howell, T. P. Brent, and L. C. Harris
Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins
Mol. Cancer Ther., January 1, 2005; 4(1): 61 - 69.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
V. Valinluck, H.-H. Tsai, D. K. Rogstad, A. Burdzy, A. Bird, and L. C. Sowers
Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2)
Nucleic Acids Res., August 9, 2004; 32(14): 4100 - 4108.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.